FCGR2B and hepatocellular carcinoma: Accordingly, Campos-Carrascosa and colleagues treated HCC-derived TILs with an Fc-engineered αOX40 human IgG1 antibody, termed αOX40_v12, that contained six mutations leading to increased affinity to FcγRIIB (E223D, G237D, H268D, P271G, Y296D, A330R).